Skip to main content
Premium Trial:

Request an Annual Quote

Weill Cornell Lands $50M in CTSA Funding

NEW YORK (GenomeWeb News) – Weill Cornell Medical College said this week that it has received a $49.6 million grant from the National Institutes of Health that renews funding for its Clinical and Translational Science Center, which conducts a wide range of research and includes a molecular sciences lab, for a second five-year period.

The award, from the National Center for Advancing Translational Sciences, will fund the CTSC, a New York City-based multi-institute consortium headed by Weill Cornell's Graduate School of Medical Sciences that was launched five years ago under NIH's first round of Clinical and Translational Sciences grants.

The aim of the center, like that of the Clinical and Translational Science Awards program, is to accelerate the clinical uptake of biomedical research discoveries by engaging in multidisciplinary studies that link basic science and clinical resources.

Julianne Imperato-McGinley, the CTSC's principal investigator and program director at Weill Cornell, said in a statement that the center provides a broad array of services, ranging from support for researchers with biostatistics and biomedical informatics, to patient resources and community engagement, to funding for promising new research areas.

"This renewal grant represents an important acknowledgement of the progress we've made in strengthening collaborative relationships between leading research institutions in New York City, nurturing the next generation of translational researchers and building an infrastructure to support further medical innovation."

The CTSC includes several core labs, including a molecular core, a general core, a multiplex analysis lab, and other specialized cores. The molecular core provides training and access to a range of services, including RNA and DNA extraction, genotyping, DNA sequencing, oligonucleotide synthesis, quantitative PCR and RT-PCR, and gene expression profiling.

The CTSC network includes researchers at Weill Cornell; New York Presbyterian Hospital; Memorial Sloan-Kettering Cancer Center; the Hospital for Special Surgery; Cornell University; Hunter College of the City University of New York's Center for the Study of Gene Structure and Function, and Schools of Public Health and Nursing, and the Animal Medical Center.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.